Holen Sie sich die Stockscreener-App
138.92
0.40%
0.56
Handel nachbörslich:
138.85
-0.07
-0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$138.36
Offen:
$138.36
24-Stunden-Volumen:
3.94M
Relative Volume:
0.54
Marktkapitalisierung:
$172.25B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
18.90
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+4.40%
1M Leistung:
+3.46%
6M Leistung:
-10.53%
1J Leistung:
+17.36%
1-Tages-Spanne:
$136.63
$139.49
1-Wochen-Bereich:
$132.01
$139.49
52-Wochen-Spanne:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
138.92 | 171.56B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,183.16 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.37 | 627.42B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.33 | 440.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.97 | 335.14B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.97 | 286.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences (NASDAQ: GILD) insider plans $3.9M share sale - Stock Titan
Gilead Sciences (NASDAQ: GILD) insider plans another 3,000-share sale - Stock Titan
In Win for Gilead, Fourth Circuit Affirms Injunction Blocking Drug Importation Scheme - IPWatchdog.com
Gilead yanks out a thorn in its side in major court ruling - thestreet.com
Simplicity Wealth LLC Invests $1.36 Million in Gilead Sciences, Inc. $GILD - MarketBeat
20,266 Shares in Gilead Sciences, Inc. $GILD Acquired by OneDigital Investment Advisors LLC - MarketBeat
Gilead Sciences stock holds steady as Q2 2026 loss sharpens focus on oncology strategy - AD HOC NEWS
N.E.W. Advisory Services LLC Takes $1.38 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
HBK Sorce Advisory LLC Invests $4.01 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Johnson Wealth Management LLC Makes New $2.41 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Flputnam Investment Management Co. Invests $8.96 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Purchases Shares of 34,604 Gilead Sciences, Inc. $GILD - MarketBeat
442,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Alberta Investment Management Corp - MarketBeat
AMG National Trust Bank Purchases Shares of 26,675 Gilead Sciences, Inc. $GILD - MarketBeat
Balm in Gilead hosts free health forum at local church to educate folks about lung cancer - WDAM-TV
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal - Seeking Alpha
One Wealth Advisors LLC Purchases New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Oppenheimer Asset Management Inc. Buys Shares of 111,624 Gilead Sciences, Inc. $GILD - MarketBeat
Summit Global Investments Buys New Shares in Gilead Sciences, Inc. $GILD - MarketBeat
Centric Wealth Management Takes $3.52 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Cornerstone Capital Inc. Purchases New Position in Gilead Sciences, Inc. $GILD - MarketBeat
ABN AMRO Bank N.V. Purchases Shares of 191,290 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead SciencesGISStock Price & News - The Motley Fool
Abundance Wealth Counselors Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
Appeals court backs Gilead in ruling that threatens overseas prescription drug programs - qz.com
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs - CNBC
Gilead Sciences, Inc. $GILD Shares Bought by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Monument Capital Management Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Confluence Wealth Services Inc. Acquires 7,986 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Lifted by Exchange Traded Concepts LLC - MarketBeat
ABN Amro Investment Solutions Has $32.39 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
4th Circ. Won't Undo Block Of Gilead-Branded Drug Imports - Law360
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine - Yahoo Finance
Gilead Scores Win to Keep Pause on Cheaper, Foreign Drug Imports - Bloomberg Law News
Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run - Yahoo Finance
Thomasville National Bank Purchases New Shares in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter
Moody Lynn Lieberson & Walker LLC Has $13.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Why Gilead Sciences (GILD) Is Back In The Spotlight - Yahoo Finance
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call - Yahoo Finance
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics - Yahoo Finance
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Sahm
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - The Manila Times
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):